The estimated Net Worth of Anne M Mulcahy is at least 2.09 百万$ dollars as of 28 May 2024. Ms. Mulcahy owns over 135 units of Johnson & Johnson stock worth over 109,111$ and over the last 21 years she sold JNJ stock worth over 1,624,136$. In addition, she makes 359,979$ as Lead Independent Director at Johnson & Johnson.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ms. Mulcahy JNJ stock SEC Form 4 insiders trading
Anne has made over 19 trades of the Johnson & Johnson stock since 2005, according to the Form 4 filled with the SEC. Most recently she bought 135 units of JNJ stock worth 100,584$ on 28 May 2024.
The largest trade she's ever made was exercising 599,400 units of Johnson & Johnson stock on 1 April 2009 worth over 98,793,108$. On average, Anne trades about 17,868 units every 60 days since 2003. As of 28 May 2024 she still owns at least 662 units of Johnson & Johnson stock.
You can see the complete history of Ms. Mulcahy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anne Mulcahy biography
Anne M. Mulcahy serves as Lead Independent Director of the Company. She was Chairman and Chief Executive Officer of Xerox Corporation (business equipment and services) until July 2009, when she retired as CEO after eight years in the position. Prior to serving as CEO, Ms. Mulcahy was President and Chief Operating Officer of Xerox. She also served as President of Xerox's General Markets Operations, which created and sold products for reseller, dealer and retail channels. Earlier in her career at Xerox, which began in 1976, Ms. Mulcahy served as Vice President for Human Resources with responsibility for compensation, benefits, human resource strategy, labor relations, management development and employee training; and as Vice President and Staff Officer for Customer Operations, covering South America and Central America, Europe, Asia and Africa. Ms. Mulcahy was the U.S. Board Chair of Save the Children from March 2010 to February 2017, and was appointed as a Trustee in February 2018.
What is the salary of Anne Mulcahy?
As the Lead Independent Director of Johnson & Johnson, the total compensation of Anne Mulcahy at Johnson & Johnson is 359,979$. There are 13 executives at Johnson & Johnson getting paid more, with Alex Gorsky having the highest compensation of 25,365,800$.
How old is Anne Mulcahy?
Anne Mulcahy is 67, she's been the Lead Independent Director of Johnson & Johnson since 2012. There are 5 older and 27 younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Ronald Williams, 70, who is the Independent Director.
What's Anne Mulcahy's mailing address?
Anne's mailing address filed with the SEC is C/O GRAHAM HOLDINGS 1300 NORTH 17TH ST., SUITE 1700, ARLINGTON, VA, 22209.
Insiders trading at Johnson & Johnson
Over the last 22 years, insiders at Johnson & Johnson have traded over 59,929,946$ worth of Johnson & Johnson stock and bought 21,998 units worth 2,578,685$ . The most active insiders traders include Hubert Joly、Anne M Mulcahy、Alex Gorsky. On average, Johnson & Johnson executives and independent directors trade stock every 21 days with the average trade being worth of 4,572,436$. The most recent stock trade was executed by Robert J Decker on 30 August 2024, trading 5,635 units of JNJ stock currently worth 563,838$.
What does Johnson & Johnson do?
Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.
What does Johnson & Johnson's logo look like?
Complete history of Ms. Mulcahy stock trades at LPL Inc、Graham Co、Johnson & Johnson、Target Corp、Williams-Sonoma、Xerox Corp
Johnson & Johnson executives and stock owners
Johnson & Johnson executives and other stock owners filed with the SEC include:
-
Alex Gorsky,
Chairman of the Board, Chief Executive Officer -
Paulus Stoffels,
Vice Chairman- Executive Committee, Chief Scientific Officer -
Joaquin Duato,
Vice Chairman - Executive Committee -
Joseph Wolk,
Chief Financial Officer, Executive Vice President -
Jennifer Taubert,
Executive Vice President - Worldwide Chairman, Pharmaceuticals -
Michael Ullmann,
Executive Vice President, General Counsel -
Alex Gorsky,
Exec. Chairman -
Peter Fasolo,
Chief Human Resource Officer, Executive Vice President -
Dr. Paulus A. Stoffels M.D., Ph.D.,
Chief Scientific Officer -
Joaquin Duato,
CEO & Director -
Joseph J. Wolk CPA,
Exec. VP & CFO -
Joseph J. Wolk C.P.A.,
Exec. VP & CFO -
Jennifer L. Taubert,
Exec. VP & Worldwide Chairman of Pharmaceuticals -
Anne Mulcahy,
Lead Independent Director -
Charles Prince,
Independent Director -
Mary Beckerle,
Independent Director -
Ronald Williams,
Independent Director -
D. Scott Davis,
Independent Director -
A. Eugene Washington,
Independent Director -
Jennifer Doudna,
Independent Director -
Mark McClellan,
Independent Director -
Ian Davis,
Independent Director -
Marillyn Hewson,
Independent Director -
Mark Weinberger,
Independent Director -
Hubert Joly,
Independent Director -
Christopher DelOrefice,
Vice President, Investor Relations -
Kathryn Wengel,
Executive Vice President, Chief Global Supply Chain Officer -
Michael Sneed,
Executive Vice President - Global Corporate Affairs and Chief Communication Officer -
Thibaut Mongon,
Executive Vice President, Worldwide Chairman, Consumer -
Ashley McEvoy,
Executive Vice President - Worldwide Chairman, Medical Devices -
Dr. Guy J. Lebeau M.D.,
Group Chairman of MD&D Bus. - EMEA -
Dr. Peter M. Fasolo Ph.D.,
Exec. VP & Chief HR Officer -
Michael H. Ullmann,
Exec. VP & Gen. Counsel -
Jessica Moore,
VP of Investor Relations -
Ashley Watson,
Chief Compliance Officer -
James Swanson,
Exec. VP & Global CIO -
Robert J. Decker Jr.,
Controller & Chief Accounting Officer -
James Cullen,
Director -
Stephen J Cosgrove,
-
Leo F Mullin,
Director -
Michael M E Johns,
Director -
Robert J Decker,
VP Corporate Controller -
Elizabeth Forminard,
Executive VP, General Counsel -
Ronald A Kapusta,
Controller, CAO -
Susan L Lindquist,
Director -
Gary J Pruden,
Exec VP, WW Chair, Med Devices -
William D Perez,
Director -
Jorge S. Mesquita,
Exec VP, WW Chair, Consumer -
Dominic J Caruso,
Chief Financial Officer -
Timothy Schmid,
EVP, WW Chair, MedTech -
Mary Sue Coleman,
Director -
David Satcher,
Director -
William C Weldon,
Chairman/CEO -
Arnold G Langbo,
Director -
Russell C Deyo,
Vice President, Administration -
Kaye I Foster Cheek,
VP, Human Resources -
Colleen A Goggins,
Member, Executive Committee -
Sherilyn S Mc Coy,
Member, Executive Committee -
Donald M Jr. Casey,
Member, Executive Committee -
Nicholas J Valeriani,
Vice President,Human Resources -
Christine A Poon,
Executive Committee Member -
Joseph C Scodari,
Executive Committee Member -
Steven Reinemund,
Director -
Ann Dibble Jordan,
Director -
Robert J Darretta,
Member, Executive Committee -
Per A Peterson,
Executive Committee Member -
Michael J Dormer,
Member, Executive Committee -
Joann Heffernan Heisen,
Member, Executive Committee -
Gerard N Burrow,
Director -
Henry B Schacht,
Director -
M Judah Folkman,
Director -
Roger S Fine,
Vice President General Counsel -
James T Lenehan,
Vice Chairman -
Brian D Perkins,
Executive Committee Member -
Robert N Wilson,
-
Nadja West,
Director -
Vanessa Broadhurst,
EVP, Global Corp Affairs -
Mathai Mammen,
EVP, Pharm, R&D -
William Hait,
EVP, Chief EI and Med Officer -
Darius Adamczyk,
Director -
James D. Swanson,
EVP, CIO -
John C Reed,
EVP, Innovative Medicine, R&D -
Paula A Johnson,
Director -
Eugene A. Woods,
Director